ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
Abstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Does Helping Others Always Benefit Health? Longitudinal Evidence on the Relationship between Helping Behavior and Depression: The Mediating Role of Life Satisfaction and the Moderating Effect of IADL.Depression and anxiety · 2024Article
- Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction.Cancer medicine · 2022Article
- Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.Current treatment options in oncology · 2019Review
- Testing of a Tool for Prostate Cancer Screening Discussions in Primary Care.Frontiers in oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Izak FaienaIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Stuart HoldenIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Mathew R CooperbergIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Stuart HoldenIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Howard R SouleIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Jonathan W SimonsIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Todd M MorganIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
David F PensonIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Alicia K MorgansIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Maha HussainIzak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.
Funding
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9MNCI NIH HHS P50 CA180995
Abstract
PubMed holds no abstract for this paper.
Indexed as
Early Detection of CancerHumansKallikreinsMaleProstate-Specific AntigenProstatic NeoplasmsKallikreinsKLK3 protein, humanProstate-Specific Antigen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.